Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitors (CNIs) tacrolimus and cyclosporine are widely used
immunosuppressive drugs characterized by high pharmacokinetic and pharmacodynamic …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature
for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Neonates, infants, and children differ from adults in many aspects, not just in age, weight,
and body composition. Growth, maturation and environmental factors affect drug kinetics …

De novo donor-specific antibodies (dnDSAs) have been associated with reduced graft
survival. Tacrolimus (TAC)–based regimens are the most common among …

Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a
narrow therapeutic range and demonstrates wide interindividual variability in …